Could Dupilumab Help Treat Depression? New Study Explores Immune Link
Mount Sinai team explores immune connections between eczema and depression
Researchers at the Icahn School of Medicine at Mount Sinai are investigating a possible immune system link between atopic dermatitis and major depressive disorder (MDD), with early results pointing to a surprising overlap in inflammatory signals that have traditionally been associated with skin disease (Source: Icahn School of Medicine at Mount Sinai press release).
How a cross‑discipline conversation got started
The project began when a psychiatry team led by James Murrough, MD, PhD, observed elevated inflammatory cytokines in the blood of patients with treatment‑resistant depression, prompting questions about whether immune activity could be part of depression’s biology (Source: Icahn School of Medicine at Mount Sinai press release).
Emma Guttman, MD, PhD, chair of dermatology at Mount Sinai, suggested widening the comparison beyond the usual skin‑brain reference point of psoriasis — which is often linked to IL‑17 — to include atopic dermatitis, representing the opposite end of the immune spectrum, and to test a larger panel of cytokines (Source: Icahn School of Medicine at Mount Sinai press release).
What the team found in the blood
The investigators measured multiple circulating immune proteins and reported a notable pattern: while IL‑17 was only modestly elevated, type‑2 cytokines such as IL‑13 were markedly higher in people with MDD — a profile more commonly associated with atopic inflammation than with psoriasis (Source: Icahn School of Medicine at Mount Sinai press release).
These results suggest that at least a subset of people with depression show immune signals resembling those seen in allergic or atopic conditions, rather than the IL‑17–driven signature that has previously colored thinking about inflammation and mood disorders (Source: Icahn School of Medicine at Mount Sinai press release).
Computer modeling points to a potential treatment target
Using computational approaches, the team modeled how blocking type‑2 signaling might affect the immune profile observed in depressed patients, and concluded that antagonizing the IL‑4/IL‑13 pathway could theoretically normalize a large portion — up to 100% in their model — of the measured immune abnormalities (Source: Icahn School of Medicine at Mount Sinai press release).
That pathway is the target of dupilumab (brand name Dupixent), a monoclonal antibody that blocks the shared receptor for IL‑4 and IL‑13 and is approved for several type‑2 driven conditions including moderate‑to‑severe atopic dermatitis (Source: Regeneron Pharmaceuticals, Dupixent prescribing information).
From models to a funded clinical trial
On the strength of the immune profiling and modeling, the researchers secured funding to test whether blocking IL‑4/IL‑13 signaling improves mood symptoms in people with MDD who do not have a concurrent inflammatory skin disease (Source: Icahn School of Medicine at Mount Sinai press release).
The planned clinical trial will evaluate three key outcomes: symptomatic change in depression, shifts in circulating immune markers, and modulation of brain circuits related to mood using functional MRI (fMRI), with partial support from the Wellcome Trust (Source: Icahn School of Medicine at Mount Sinai press release; Wellcome Trust funding announcement).
Why this matters for psychiatry
Beyond the immediate question of whether an anti‑type‑2 drug can reduce depressive symptoms, the investigators frame their work as part of a larger effort to move psychiatry toward biologically defined subtypes of mental illness rather than the current, largely symptom‑based categories (Source: Icahn School of Medicine at Mount Sinai press release).
At present there are no widely accepted, validated biological subtypes for psychiatric disorders, and most antidepressant prescribing remains empirical — chosen by clinical judgment, trial-and-error, and symptom patterns rather than blood tests (Source: National Institute of Mental Health commentary on biomarker development in psychiatry).
Murrough and colleagues note that discussions are underway among experts and diagnostic workgroups about whether an inflammatory subtype of depression is supported by enough data to be formally recognized in future diagnostic manuals such as the DSM (Source: American Psychiatric Association, DSM workgroup communications and public materials).
Clinical and practical implications
The researchers also took aim at a common clinical assumption: that depression in people with inflammatory skin disease is primarily a psychological reaction to living with chronic illness.
Guttman and Murrough caution that this reactive framing can obscure shared biological causes; if common immunologic mechanisms help drive both skin inflammation and mood symptoms, clinicians may need to rethink screening thresholds and referral patterns between dermatology, psychiatry, and primary care (Source: Icahn School of Medicine at Mount Sinai press release).
In practice, that could mean earlier mental health screening for patients with marked type‑2 inflammation, and conversely, consideration of inflammatory testing for people with depression who show treatment resistance or systemic inflammatory markers (Source: Icahn School of Medicine at Mount Sinai press release; National Institute of Mental Health guidance on inflammation and depression research).
Limitations and next steps
The investigators emphasize that these findings are preliminary: blood cytokine patterns don’t yet prove causation, and computational predictions must be validated in prospective clinical trials (Source: Icahn School of Medicine at Mount Sinai press release).
The ongoing trial will be important not only for testing a specific drug hypothesis but also for refining which patients might benefit from immune‑targeted approaches, defining measurable biomarkers, and determining how immune changes map onto changes in brain function and mood (Source: Icahn School of Medicine at Mount Sinai press release; Wellcome Trust funding announcement).
What patients and clinicians should know
Patients living with atopic dermatitis or other inflammatory skin diseases who experience mood changes should be taken seriously: those symptoms are not necessarily only a normal reaction to chronic illness and may reflect underlying biological processes that benefit from assessment and treatment (Source: Icahn School of Medicine at Mount Sinai press release).
Clinicians across specialties are encouraged to communicate and consider cross‑referral when inflammatory markers or persistent psychiatric symptoms are present, while awaiting the results of clinical trials that will clarify whether specific immunotherapies help treat a subset of depression (Source: Icahn School of Medicine at Mount Sinai press release).
Conclusion
The Mount Sinai work highlights a potentially important overlap between type‑2 inflammation and depression, reframing how researchers think about immune signals in psychiatric disease and opening a path to trials that could change how we define and treat some forms of MDD (Source: Icahn School of Medicine at Mount Sinai press release).
Whether blocking IL‑4/IL‑13 signaling with agents like dupilumab will translate into meaningful clinical benefit for depression remains unknown, but the new trial will provide data that could reshape diagnostic thinking and encourage more biologically guided psychiatry (Source: Regeneron Pharmaceuticals, Dupixent prescribing information; Wellcome Trust funding announcement).
Sources
- Icahn School of Medicine at Mount Sinai press release / news materials on the collaboration between Emma Guttman and James Murrough and the inflammatory profiling of MDD (Source: Icahn School of Medicine at Mount Sinai press release).
- Regeneron Pharmaceuticals, Dupixent (dupilumab) prescribing information and approval details (Source: Regeneron Pharmaceuticals, Dupixent prescribing information).
- Wellcome Trust funding announcement regarding support for research into inflammation and mental health (Source: Wellcome Trust funding announcement).
- National Institute of Mental Health materials on biomarkers, inflammation, and depression research (Source: National Institute of Mental Health guidance and commentary).
- American Psychiatric Association public materials about DSM revision processes and workgroups (Source: American Psychiatric Association communications).